A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

Trial Profile

A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs MM 310 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2017 According to a Merrimack Pharmaceuticals media release, safety data and recommended Phase 2 dose from this study is expected in second half 2018.
    • 10 May 2017 According to a Merrimack Pharmaceuticals media release, the company expects to report safety data and a recommended Phase 2 dose from this study in 2018.
    • 23 Mar 2017 According to a Merrimack Pharmaceuticals media release, the company expects to report data from part one of the study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top